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ABSTRACT
Objective: To give an insight into the structural and
methodological approaches used in published decision-
analytic models evaluating interventions in Parkinson’s
disease (PD) and to derive recommendations for future
comprehensive PD decision models.
Methods: A systematic literature review was performed
to identify studies that evaluated PD interventions using
mathematical decision models. Using a standardized
assessment form, information on the study design, meth-
odological framework, and data sources was extracted
from each publication and systematically reported.
Strengths and limitations were assessed.
Results: We identiﬁed eight studies that used mathemat-
ical models to evaluate different pharmaceutical (n = 7)
and surgical (n = 1) treatment options in PD. All models
included economic evaluations. Modeling approaches
comprised mathematical equations, decision trees, and
Markov models with a time horizon ranging from 5 years
to lifetime. All based progression on the evolution of clin-
ical surrogate endpoints. Treatment effects were either
modeled via reduction of symptomatic progression and/or
initial symptomatic improvement or via reduction of
adverse effect rates. No model is currently available that
encompasses both the underlying biologic disease pro-
gression and the spectrum of all relevant complications
and also links them to patient preferences and economic
outcomes.
Conclusions: Models have been successfully applied to
evaluate PD treatments. However, currently available
models have substantial limitations. We recommend that
a comprehensive, generic, and ﬂexible decision model for
PD that can be applied to different treatment strategies
should consider a large spectrum of clinically relevant
outcomes and complications of the disease during a suf-
ﬁciently long time horizon, include PD-speciﬁc mortality,
systematically evaluate uncertainty including heterogene-
ity effects, and should be validated by independent data
or other models. Approaches to model treatment effects
included reduction of symptomatic progression, initial
symptomatic improvement, or reduction of adverse
effects. We believe that structural bias could be avoided if
underlying disease progression and treatment effects on
symptoms are modeled separately.
Keywords: cost-effectiveness analysis, decision analysis,
Parkinson’s disease, systematic review.
Introduction
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorders with a prevalence of 66
to 258 per 100,000 [1–5]. The clinical picture is
characterized by (resting) tremor, slowness of move-
ment (bradykinesia), rigidity, and impairment of
balance reﬂexes (postural instability). One crucial
milestone during disease progression is the advent
of motor complications [6], which occur in approx-
imately 50% of the patients after disease duration
of 3 to 5 years [7]. Other complications include psy-
chiatric disturbances such as depression, dementia,
and hallucinations and gastrointestinal symptoms,
which may have a high impact on patient’s activities
of daily living and health-related quality of life [8].
Medical treatment aims to restore the failure of
dopamine production by using levodopa, dopamine
agonists, or inhibitors of dopamine degradation
(MAO-B inhibitors, COMT-inhibitors) [9–11]. In
addition, anticholinergic drugs as well as N-methyl-
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D-aspartate (NMDA) antagonists (amantadine) are
used. Recently, a resurgence of interest in surgical
procedures such as pallidotomy and deep brain
stimulation has arisen [12,13]. Although pharma-
ceutical and surgical therapies can alleviate signs
and symptoms of PD, the disease relentlessly
progresses. Therefore, the long-term effect of treat-
ment on clinical symptoms and health-related qual-
ity of life (QoL) is paramount in evaluating PD
interventions. However, most clinical trials have a
short time horizon and use surrogate endpoints or
focus only on speciﬁc complications instead of
assessing the entire spectrum of the disease and the
impact on the patient’s QoL. Therefore, mathemat-
ical models must be used to link the short-term clin-
ical outcomes from clinical trials with evidence for
the long-term progression of the disease, patient
preference data, and costs to guide clinicians and
health-care policy decision-makers [14–18]. How-
ever, modeling intervention effects on PD is highly
complex. In particular, the wide spectrum of PD
symptoms and treatment complications and the
lifelong progression of disease require the combina-
tion of different health outcomes and the extrapo-
lation of them beyond the time horizon of clinical
trials.
To date, several decision-analytic or other types
of mathematical models for interventions in
patients with PD have been published, but to our
knowledge, there are no published reviews of PD
models. Therefore, we sought to provide decision
analysts and clinicians interested in formal medical
decision making with an insight into the structural
and methodological approaches used in PD decision
modeling including their strengths and limitations.
This inspection is intended to help them to improve
further modeling or to select the optimal structural
approach to answer their speciﬁc research question.
We did not intend to systematically compare the
effectiveness or cost-effectiveness of interventions.
Finally, we derive recommendations for the devel-
opment of comprehensive decision models evaluat-
ing interventions in PD.
Methods
Identiﬁcation of  Relevant Studies
We performed a systematic literature search in elec-
tronic databases using a combined search strategy,
including the following terms: “decision analysis,”
“decision-analytic,” “decision model,” “health care
model,” “health care evaluation model,” “decision
tree,” “Markov model,” “cost-effectiveness,” “cost-
utility,” “cost-beneﬁt,” “cost-minimiz(s)ation,”
“QALY,” and “Parkinson.” The search was ﬁrst
performed on the databases Medline and
PreMedline (1966 to July 2002), Current Contents
(all editions, 1993 to July 2002), Embase (1991 to
July 2002), EconLit (1969 to July 2002), and the
Cochrane’s database of systematic reviews (to 2nd
quarter 2002). A more broadly speciﬁed search was
performed on the databases DARE (Database of
Abstracts of Reviews of Effectiveness), NHS EED
(Economic Evaluation Database), and HTA (Health
Technology Assessment) of the United Kingdom’s
NHS Centre for Reviews and Dissemination (http://
www.nhscrd.york.ac.uk). In addition, we examined
previous reviews and reference lists of identiﬁed
studies. There was no restriction on language or
publication time.
One of the inclusion criteria for this review was
that the study was based on a decision-analytic
model or any other type of mathematical health-
care model evaluating therapeutic interventions for
PD. Regarding the term “model,” we used a modi-
ﬁed deﬁnition recently given by the “ISPOR Task
Force on Good Research Practices—Modeling Stud-
ies” [19], and deﬁned health care evaluation model
as an analytic methodology that accounts for health
outcomes over a deﬁned time and across a deﬁned
population, whose purpose is to estimate the effects
of an intervention on valued health consequences
and/or costs. This deﬁnition includes decision trees,
Markov models, and models based on mathemati-
cal equations. Purely descriptive studies or studies
using models only as an illustration or in a tutorial
were excluded. Only published studies were
included in the review. Studies published only as
abstracts without providing full information about
the model were not included [20–22].
Data Extraction and Model Assessment
We  used  a  standardized  assessment  form,  which
was based on guidelines and recommendations for
decision modeling and cost-effectiveness analysis
[17,23,24] to extract data from included studies.
The form comprised the following domains deﬁned
prior to the study:
• Study reference;
• Target population, country, setting;
• Decision-analytic framework;
• Data sources;
• Model validation;
• Results;
• Limitations;
• Conclusions;
• Funding.
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The study reference included authors, year of pub-
lication, reference, and the setting (country and
year). The decision-analytic framework comprised
information about target population, study ques-
tion/objectives in the author’s words, study type,
compared strategies, time horizon, outcome meas-
ures, brief model design, statistical analysis, per-
spective, and discounting (annual discount rate).
The domain data sources listed data sources for epi-
demiology/natural history, efﬁcacy, quality of life/
utilities, costs, and other data. Furthermore, key
structural and numeric assumptions as well as
efforts of model validation were stated. Base-case
results for effectiveness, costs, and the cost-
effectiveness relation as well as results from sensi-
tivity analyses were extracted. We extracted major
limitations of each publication, as recognized by the
investigators or as commented upon by the asses-
sors. Finally, the author’s main conclusions were
summarized.
All data were independently assessed by three of
the  authors  (Siebert,  U,  Bornschein,  B,  Walbert,
T) using the standardized assessment form. The
extracted data were summarized in evidence tables.
Furthermore, a model and study assessment was
performed in a qualitative fashion and the assessor’s
comments on model features and study quality were
summarized in a brief commentary for each publi-
cation. If extracted information or judgment of
model assessment differed between two of the
reviewers, the study was completely reassessed by
an expert in methodology and neurology (Dodel,
RC) and the issue was discussed among the group to
achieve agreement.
Results
Systematic Literature Search
The systematic literature search was performed in
July 2002 and yielded 18 hits in Medline and 20 hits
in Current Contents. Searches in the other data-
bases did not lead to additional studies. Only 5 of
the 18 studies identiﬁed in the Medline search were
modeling studies; they are included in the review.
The other 13 were excluded because they addressed
neuropsychological [25–29], physiological [30],
and nursing aspects [31]. Several studies were not
included because they were randomized clinical tri-
als (RCT) or cost studies which were not based on
a model [32–36] or they used a model only for illus-
tration purposes [37].
In the Current Contents search, 3 of the 20 iden-
tiﬁed studies were modeling studies. All 3 had been
previously identiﬁed in the Medline search. The
remaining 17 studies were excluded because they
addressed neuropsychological [26–28], biological
[30], or nursing aspects [31,38]. Two articles pre-
sented RCT results [33,34], 7 did not contain deci-
sion models [36,39–44], and 2 described models
only for illustration purposes [37,45].
The manual search of reference lists did not lead
to additional documents, but expert advice and an
updated search in February 2003 revealed 3 addi-
tional relevant studies. One study was published in
a recently founded journal [46] and the other 2 were
published in October 2002 [47] and February 2003
[48]. Overall, 8 studies were included in the system-
atic review and formal data extraction [46–53].
Systematic Description and Assessment of  Studies
Table 1 summarizes the methods and ﬁndings of the
8 studies included in the systematic assessment.
Table 2 lists the analytic framework and model fea-
tures. In the following, a brief narrative description
is given for each study, highlighting methodological
strengths and limitations and quality of input data.
We also highlighted features we thought to be of
speciﬁc methodological interest or from which we
can learn for future modeling.
Hoerger et al. 1998. Hoerger et al. [49] performed
a cost-utility study evaluating the use of the
dopamine agonist pramipexole in two settings. The
authors compared 1) pramipexole with no levodopa
therapy in the early stages of PD; and 2) pramipex-
ole plus levodopa with levodopa monotherapy in
advanced PD. Two separate models for early and
advanced PD were based on a set of mathematical
equations. United Parkinson’s Disease Rating Scale
(UPDRS), which includes information on patient’s
history, physical examination, and complications,
was used as surrogate for progression of disease and
modeled as a function of treatment and time from
onset of PD. In these equations, introduction of
pramipexole and/or levodopa was assumed to
instantaneously improve UPDRS scores and par-
tially attenuate  UPDRS-based  progression  rates.
In further equations, quality-adjusted life years
(QALY) and lifetime direct and indirect costs were
expressed as a function of UPDRS scores. Applying
multivariate regression analysis to clinical trial data
and survey data on UPDRS scores, costs, and QoL
ﬁt the mathematical equations. The authors used
probit models to predict hospital visits and working
status, logarithmic regression for costs, and linear
regression for utilities.
For both comparisons, the incremental cost-
utility-ratio (ICUR) was below US$35,000 per
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QALY gained. The authors concluded that the use
of pramipexole is cost-effective in either early-stage
PD or in later stages in combination with levodopa.
The authors mentioned that the model might be
improved by including complications and other
modern therapies. They also discussed the limited
predictive value of the regression equations used
(adjusted R-square 5–26%).
In this transparently reported study, costs and
health  outcomes  are  represented  by  a  detailed  set
of mathematical equations. One strength of the
authors’  use  of  mathematical  equations  is the
clear and transparent presentation and the explicit
regression-based parameterization under several
conservative assumptions, which have been tested
in extensive sensitivity analyses. The fact that the
model is based on equations reﬂecting UPDRS
scores limits its ﬂexibility and applicability for treat-
ments that have an effect on speciﬁc disease com-
ponents or events not sufﬁciently included in or
adequately weighted by the UPDRS.
Davey et al. 2001. Davey et al. [50] performed a
cost-effectiveness study comparing the dopamine
agonists pergolide and bromocriptine in patients
with PD. The authors developed a Markov model
with a 10-year time horizon based on Hoehn and
Year (HY) stages. HY staging is a well-established
PD classiﬁcation scheme, evaluated in the presence
(HY on) or absence (HY off) of treatment. This
Markov model included HY-on stages I–V and
death and was based on HY-on-speciﬁc progression
rates derived from an Australian 12-year cohort
study. Efﬁcacy was taken from one randomized clin-
ical trial, which was selected among 5 identiﬁed
RCTs. Resource utilization was based on an expert
panel survey. The clinical outcome (time in stages
HY-on I–III) of the comparator bromocriptine was
based on the initial distribution of HY-on stages and
progressions from the cohort study. The HY-on dis-
tribution of the pergolide branch was modeled
using a 19% absolute risk difference for HY
improvement, which was reported in the RCT. The
authors assumed no treatment effect on progression
rates conditional on HY-on stage. In the base case,
HY-on distributions of both treatments were set to
be equal after 2 years, varied from 0.5 to 10 years in
scenario analyses.
Results showed improved effectiveness and lower
health-care costs for pergolide (dominance). The
authors concluded that pergolide is cost-saving and
more efﬁcacious than bromocriptine. Savings due to
prevented or deferred complications offset the small
additional drug costs of pergolide.
The model and its parameters were described in
detail. The strength of the model and its applicabil-
ity in other evaluations is given by the implemen-
tation of HY-on stages, which is a clinical
classiﬁcation applied in many studies. HY-on, how-
ever, is not a marker for the disease-underlying nat-
ural progression and empiric treatment efﬁcacy data
were restricted to HY-on stages I–III. Therefore, the
authors were forced to extrapolate progression for
HY-on IV–V. In addition, the initial (i.e., before
treatment) HY-on distribution remained unclear.
However, sensitivity analyses adequately addressed
the uncertainty on duration of efﬁcacy. No sensitiv-
ity analyses were performed on the magnitude of
efﬁcacy, which was assumed to be additive (absolute
risk difference) regardless of the baseline risk. Nei-
ther background mortality rates of the general pop-
ulation nor QoL data were considered in the model.
To  adapt  probabilities  and  risk  differences  to  the
6-month cycle length, probabilities were simply
divided by the number of intervals instead of using
the declining exponential approximation of life
expectancy (DEALE) approach within intervals.
Nuijten et al. 2001. Nuijten et al. [51] performed a
cost-utility and cost-effectiveness study on the effect
of the complementary use of the COMT-inhibitor
entacapone in PD patients suffering from severe
ﬂuctuations in the Netherlands. The authors used a
Markov model with a 5-year time horizon and
Markov states based on severity of ﬂuctuations
expressed by off time (£25% vs. >25% per day).
Markov state-speciﬁc data on duration of the dis-
ease, which were obtained from a cross-sectional
study, were transformed into progression rates
using the DEALE approach. Based on RCT data for
entacapone, improvement was restricted to the ﬁrst
6 months in the model. Utilities were estimated
from patient preference data assessed in a US study,
which was designed for this project. Resource utili-
zation patterns were based on a German retrospec-
tive cost study and drug costs were assessed along
RCTs.
Entacapone was more effective and less costly
than usual care (dominance). These results were
robust in extensive sensitivity analyses performed
on the relevant model parameters.
This is a well-performed study with explicit,
plausible, and conservative assumptions. A major
strength of this model is its simplicity and parsi-
mony. Also, the Markov state classiﬁcation based
on daily off time reﬂects a very relevant aspect of
QoL. However, utilities were assessed in two move-
ment disorder clinics and one private neurology
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practice in the US and the transferability to patients
in the Netherlands may be questionable. The fact
that progression rates were estimated from a cross-
sectional study was adequately addressed in sensi-
tivity analyses. The model is limited by the binary
off-time health state, which does not reﬂect the
entire spectrum of disease severity and also does not
reﬂect natural history of disease stages. Therefore,
QoL effects and costs of speciﬁc adverse effects,
complications, and concomitant illness cannot be
analyzed with this version of the model. Finally, the
5-year time horizon may be too short to reﬂect the
societal perspective.
Tomaszewski  and  Holloway  2001.  Tomaszewski
and Holloway [52] performed a cost-utility study
for a new surgical treatment option, deep brain
stimulation (DBS), in the advanced stage of PD. The
study was performed at an early stage in the life-
cycle of this technology. The authors developed a
lifetime Markov model based on states reﬂecting
care within the nursing home versus outside of it.
The Markov model was embedded in a decision tree
reﬂecting surgical complications. In the model, DBS
improves QoL (based on UPDRS score improve-
ment) in the initial period and then the effect grad-
ually declines approaching the level of patients with
best medical treatment.
The base case ICUR for DBS is US$49,000 per
QALY. The authors consider DBS a cost-effective
therapy alternative, given a surplus of QoL of at
least 18%. However, data for this new technique
are extremely sparse and cover only about 2 years
of follow-up. QoL data rely on a small sample of
patients, but have a very strong impact on ICUR.
Therefore, these preliminary results indicate that
further data with special respect to utilities are
needed prior to recommendation of this technology.
In this carefully performed study, modeling is
used in the situation of sparse clinical, economic,
and outcome data. ICUR relied strongly on QoL
values of DBS patients. QoL over time and several
other crucial parameters (e.g., DBS-related compli-
cations and generator replacement intervals) were
based on expert opinion. Therefore, results should
be interpreted with caution and the authors indi-
cated the need for further utility data. The
strength of this model lies in its transparent mode-
ling assumptions in the situation of sparse treat-
ment effect data and sensitivity analyses
underlining the uncertainty. The model is limited
by the use of UPDRS scores as the relevant out-
come. Side effects of the DBS were modeled as sur-
gical death and permanent and temporary
complications and accordingly adjusted for QoL.
The effect of the anatomic stimulation target (sub-
thalamic nucleus vs. globus pallidum internum) on
costs and clinical effect was not adequately consid-
ered in the model.
Shimbo et al. 2001. Shimbo et al. [53] performed a
cost-utility study comparing the adjuvant use of the
dopamine agonists bromocriptine or pergolide with
levodopa monotherapy. The authors applied a 10-
year Markov model consisting of 6 Markov states
(HY-on stages I–V and death). The model assumed
an improvement of one HY-on stage in a certain
proportion of a cohort of patients with HY-on
stages II–V associated with the introduction of the
dopamine agonist. Data on resource utilization and
utilities were determined in a survey accompanying
the study.
The results of this study indicated that both
dopamine agonists were cost-effective only in the
later stages of the disease, i.e., HY-on stages III or
higher. Generic preparations of bromocriptine with
50% lower costs compared to the original formu-
lation were more effective and cost saving even in
HY-on stage II (dominant) when compared to lev-
odopa alone.  In  sensitivity  analyses,  drug  costs
and effectiveness showed substantial inﬂuence on
ICURs.
This is a carefully performed study with mostly
conservative assumptions. However, some aspects
of clinical routine were not considered, such as the
increase in drug dose was not modeled. This study is
especially relevant for the Japanese health-care con-
text, because speciﬁc dosage patterns and prices
were carefully assessed in Japan. Without substan-
tial modiﬁcations, though, the model has limited
use for evaluations outside of Japan, because
parameters are not generalizable. For example, the
model does not include dopamine agonist mono-
therapy, because this was not approved in Japan. In
addition, there were substantial differences when
comparing dosage and therapy costs for Japan ver-
sus other countries.
Linna  et al.  2002. Linna et al. [46] performed a
cost-utility study investigating not only the cost-
effectiveness of adjunct entacapone to levodopa,
and any further PD medication, but also the extent
of uncertainty associated with the result by Monte
Carlo resampling methods. They developed a
Markov model consisting of 8 Markov states (mod-
iﬁed HY-on stages and death), which used treat-
ment- and HY-speciﬁc transition probabilities from
two RCTs with a follow-up of 6 months. Assuming
a constant treatment effect over time, these transi-
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tion probabilities were extrapolated to a time hori-
zon of 5 years.
This study showed that adjunctive entacapone is
cost-saving and associated with higher QoL values
in 87.5% of the simulations. Variation in transition
probabilities contributed to most of the overall
uncertainty associated with ICUR.
The model parameters used in this study were
not sufﬁciently described in the publication.
Although data sources and data assessment meth-
ods were thoroughly explained and up-to-date evi-
dence was considered, no model input parameters
were reported for initial cohort distribution, transi-
tion probabilities, utilities, and costs. As strength,
the investigators extensively explored uncertainty
by Monte Carlo simulation and displayed cost-
effectiveness planes with 95% conﬁdence ellipses as
well as cost-utility acceptability curves. One-way
sensitivity analyses addressing systematic rather
than random variation were not sufﬁciently
reported. Along with the Finnish 15D, a new
generic instrument for determination of health-
related quality of life was used. This instrument dif-
fers conceptually and in QoL dimensions from
other well-established instruments [54]. Therefore,
the comparability of the ICUR with that of other
studies may be problematic.
Palmer et al. 2002. Palmer et al. [47] performed a
cost-utility and cost-effectiveness study for adding
entacapone to levodopa and standard treatment in
US patients who experience off-time (re-emergence
of PD symptoms). The authors modiﬁed the
Markov model developed by Nuijten et al. [51] to
adapt it to the US setting and to add the third payer
perspective in addition to the societal perspective.
For further details, see the description of the model
in the section Nuijten et al.
In the base case, adding entacapone had an ICUR
of US$9327/QALY for the societal perspective (i.e.,
considering total costs) and US$21,213/QALY for
the third payer perspective (direct medical costs
only).
This was a well-performed study with plausible
and conservative assumptions. The model and its
parameters were clearly described. However, the
robustness of these model results is limited because
the progression rate for PD patients was estimated
from a single source, although the sensitivity anal-
ysis indicated that results were sensitive for this
parameter. The authors mentioned as a further lim-
itation the representation of off time by only two
levels (i.e., £25% vs. >25% off-time). These levels
neither discriminate the clinical course accurately
nor fully reﬂect the underlying biologic progression
of disease.
Iskedjian  and  Einarson  2003.  The study condu-
cted by Iskedjian and Einarson [48] is a cost-
minimization study in PD which examined the
economic impact of reducing dyskinesias using the
dopamine agonist ropinirole instead of levodopa
plus benserazide in treatment-naïve (de novo) PD
patients. The authors modeled along one large RCT
using 5-year clinical and economic data. Assuming
equivalent effectiveness, only costs triggered by dys-
kinesias and hallucinations were considered. Costs
over a time horizon of 5 years were compared
adopting the societal perspective and the third-
payer perspective of the Ministry of Health in
Ontario/Canada. Whereas the perspective of the
Ministry of Health considered only drug costs and
other health-care costs, the societal perspective
additionally included productivity costs and car-
egiver costs. The speciﬁc study question was
whether savings due to avoided cases of dyskinesias
offset the added cost of ropinirole. The calculation
was based on a decision-tree approach, that is, the
authors used a case-management pathway-tree
derived from empiric data and expert estimates on
the age- and regimen-speciﬁc frequencies of dyski-
nesias and hallucinations, which triggered health
care, productivity, and caregiver time.
From the societal perspective, ropinirole was
cost-saving. The authors concluded that savings due
to avoided cases of dyskinesia offset the added cost
of ropinirole. Loss of productivity was the major
factor offsetting the drug costs followed by care-
giver-associated costs. From the perspective of the
Ministry of Health, ropinirole was more expensive
than levodopa.
This study is unique in modeling the impact of
adverse effects of the drugs ropinirole and levodopa
on costs. However, the authors mention that this
was not a comprehensive analysis because only
costs triggered by adverse effects were considered
and differential impacts of the compared regimens
on QoL were not considered. Although clinical data
were derived from a large RCT, substantial cost-
and resource-utilization data were estimated by
four expert panelists, which could limit generaliza-
bility. However, most assumptions were conserva-
tive, i.e., modeled against ropinirole treatment.
Although this model is restricted to the evaluation
of dyskinesias and hallucinations, the careful eval-
uation of drug effect proﬁles might be a promising
approach for future cost-utility models that con-
sider both the effectiveness and adverse effects as
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factors inﬂuencing the outcome QALYs. An addi-
tional strength of this study was its inclusion of cost
due to lost productivity, which was based on the
human capital approach. Further sensitivity analy-
ses considering actual employment rates, around
60%, would have added valuable information to
the study. The fact that information such as age dis-
tribution was not explicitly reported may prevent
interested investigators in replicating the modeling
results. The practice of using discounting only in
sensitivity analyses and not in the base-case analysis
is not in concordance with current recommenda-
tions for cost-effectiveness studies [17]. A more
extensive use of sensitivity analyses to quantify
uncertainty would have further increased the
strength of this study.
Discussion
This systematic review and assessment of model-
based studies of treatment strategies in PD patients
includes 8 studies. All were published within the last
5 years and reﬂected the health-care systems of
different countries—Australia, Canada, Finland,
Japan, the Netherlands, and the USA (see Table 1).
The  target  populations  ranged  from  early-stage
to advanced PD patients and—depending on the
study—included treatment-naive patients as well as
patients on levodopa treatment. Seven studies eval-
uated strategies for drug therapies using dopamine
agonists (pramipexole, pergolide, bromocriptine,
ropinirole), or the COMT-inhibitor entacapone,
either alone or as an adjunct to levodopa. One study
comparing deep brain stimulation to best medical
management while this technology was in an early
state of its life-cycle based effectiveness on data
from case series. Seven studies [46,47,49–53] eval-
uated clinical beneﬁts as well as economic outcomes
and compared different strategies, and therefore,
belong to the category of complete economic eval-
uations. In 6 studies [46,47,49,51–53], the authors
reported cost-utility ratios in costs per QALY
gained. In the two remaining studies, which were a
cost-effectiveness [50] and a cost-minimization
study [48], the clinical outcome was time free of
progression to HY-on stages IV or V and costs per
patient per year, respectively. In all studies, costs
were based on resource-utilization data derived
from short- to intermediate-term clinical or cost-of-
illness studies. Long-term costs were based on
national administrative databases or expert opin-
ion. In cost-utility studies, health-state-speciﬁc util-
ities were transformed into QALYs and used in the
denominator of the cost-utility ratio. The evaluated
time horizon ranged from 5 years to lifetime and the
perspective of either society or the health care payer
was adopted. All studies showed that the investi-
gated strategy was cost-effective or even cost-saving
(i.e., more effective and less costly) compared to the
current standard of care, at least for some alterna-
tive strategies or for some of the examined scenar-
ios. However, the intention of this paper was not to
compare the effectiveness or cost-effectiveness of
interventions. Rather, our intention was to give an
insight into the “architecture” of published decision
models and to derive recommendations for future
modeling in PD.
Type of  Models and Methodological Approaches
Different model approaches and designs were used
in the assessed studies. The ﬁrst published model
consisted of a mathematical equation system in
which the equations described the progression of
disease expressed through deterioration of UPDRS
scores [49]. In further regression analyses, QoL and
costs were linked to UPDRS scores. A later model
used  decision-tree  techniques  to  calculate  costs
of illness when taking adverse drug effects into
account [48]. All remaining models were Markov
models with Markov states deﬁned by HY stages
rated during treatment (HY-on stages), on/off-time,
or nursing home status (in/out) [46,47,50–53].
The authors used different methodological
approaches to model the effect of treatment. Some
assumed an initial improvement of the new inter-
vention compared to standard care, some used
reduced progression rates with respect to the symp-
tomatic scales (e.g., HY, UPDRS), some combined
both approaches, and one study used reduced
adverse effect probabilities. Some of the models
were limited in reﬂecting the continuous character
of the progression of disease, because they included
only few Markov states. Two studies classiﬁed
patients by using the Markov states “time with
£25% off time” and “time >25% off time” [47,51].
Although this is an elegant approach to focus on a
relevant outcome, it may not fully reﬂect the spec-
trum of the disease and the related QoL. Another
study used the surrogate outcome UPDRS score as a
core model variable [49].The study on deep brain
stimulation used the binary classiﬁcation care inside
or outside nursing home [52], which seems to be a
very crude measure of deﬁning the outcome of treat-
ment. The cost-minimization study focused exclu-
sively on the economic impact of adverse effects
(e.g., dyskinesias) [48]. The remaining three studies
used HY stages under adequate treatment (HY-on)
to deﬁne the current health state of the person
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[46,50,53]. There are several advantages of this
approach. First, the entire spectrum of disease (i.e.,
early to advanced disease with its speciﬁc complica-
tions) can be considered more precisely and pro-
gression over time can be modeled in greater detail.
Second, HY-on stages are a standard clinical rating
system that is measured in many clinical trials [55].
Thus, sufﬁcient data are available to apply such a
model to different interventions and settings. The
third advantage of using health states based on HY-
on is that the HY-on stages correlate with other clin-
ical scores such as the UPDRS, complications, QoL,
and costs [5,56–59].
However, there is a fundamental problem with
using HY-on as a marker for the progression of
disease. By deﬁnition, HY-on is a classiﬁcation for
patients under adequate treatment, and therefore is
affected simultaneously by both the natural bio-
logic progression of disease and the symptomatic
response to treatment. Even valid and precise
measurement of HY-on for each treatment over
time does not allow for the isolation of the natural
progression from the treatment effect for both the
new treatment as well as the comparator (e.g., lev-
odopa treatment). This causes two methodological
problems. First, it is difﬁcult—if not impossible—
to state explicit and independent assumptions
about progression effects and treatment effects and
to evaluate the impact of these assumptions in sen-
sitivity analyses, which normally represent one of
the most important tools in decision-analytic mod-
eling. Second, the mean transition time from one
HY stage to the next takes about 2 to 3 years
[60,61], but in most clinical studies the time hori-
zons are too short to yield sufﬁcient data for
progression to advanced HY stages. Therefore,
extrapolations for the treatment effect beyond the
clinical evaluation period must be made. Although
this is a common procedure in decision analysis,
assumptions about treatment alone are not sufﬁ-
cient to project the future course of disease effects
(i.e., the difference in the progression between one
treatment and the other). The treatment effect
must still be applied to the progression in the com-
pared strategy (i.e., the baseline progression). The
use of HY-on-based Markov states in a model
forces the investigators to simultaneously extrapo-
late both baseline progression and treatment effect,
which poses the risk of making the extrapolation
speculative or introduce structural bias. Weinstein
et al. stated that, in general, structural bias is
avoided by modeling underlying disease states and
then by calibrating outputs to data on observed
clinical status [19].
If we apply this recommendation to PD, an alter-
native modeling approach that could solve this
problem is deﬁning the Markov states based on
both HY-off and HY-on data. Transition rates for
HY-off stages, which are available from progression
studies for HY-off I–V [60,61], reﬂect the natural
progression of the disease and therefore allow evi-
dence-based modeling of the progression excluding
a treatment effect. In addition, either model outputs
have to be calibrated to observed HY on data or
data on the association of HY-on and HY-off under
different treatment options have to be assessed.
Only when the underlying HY-on stages are validly
linked to HY-on outputs, such a model could be
used to predict long-term consequences for new
interventions. Once sufﬁcient knowledge about the
interaction of pathophysiologic progression and
clinical outcome under PD treatment is available,
models may also be based on histologically or
pathophysiologically deﬁned health states.
This issue is especially important for the evalua-
tion of possible beneﬁts gained from early diagnosis
(e.g., with imaging techniques such as single photon
emission computed tomography [SPECT] or posi-
tron emission tomography [PET]) in combination
with emerging neuroprotective treatments [62].
Early interventions can only be evaluated with a
model that links clinical health states (e.g., HY-on
stages) to an underlying chain of natural progres-
sion in the absence of treatment.
Time Horizon
Whereas four studies used a time horizon of only
5 years [46–48,51], 4 others used a time horizon of
10 years to lifetime [49,50,52,53]. The time horizon
chosen can have a substantial impact on health
effects and costs, and should be at least considered
in sensitivity analyses. Only a time horizon that is
long enough to cover even advanced stages of PD
(i.e., 10 years and larger) can 1) combine potential
tradeoffs between short-term gains and long-term
losses due to drug adaptation effects, and 2) yield a
reliable incremental cost-effectiveness ratio that
allows a fair comparison with other medical tech-
nologies [24].
Adverse Events and Complications of  the Disease
Adverse events play a substantial role in the treat-
ment of PD. Although Nuijten et al. [51] and
Palmer et al. [47] mentioned that adverse drug
events may inﬂuence costs substantially, none of the
research groups except Iskedjian and Einarson [48]
included branches or health states for adverse drug
events in their model. The effects of adverse events
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on QoL should also be considered in future models.
If data are lacking, sensitivity analyses should eval-
uate the need for speciﬁc pharmacoepidemiologic
studies. Tomaszewski and Holloway present an
excellent example of integrating adverse effects
after the implantation of electrodes for subthalamic
stimulation (“new” technology) [52]. As the
authors modeled adverse effects only in the “new”
technology and not in the comparator (i.e., the
adverse events from pharmacological therapy), their
results are conservative in the sense that they may
overestimate the cost-effectiveness ratio of deep
brain stimulation. Conservative modeling of the
new technology is usually the preferred analytic
approach when data are lacking.
As outlined earlier, several complications may
occur during the course of PD and these may have a
strong impact on health-care utilization and QoL.
These include behavioral disturbances and gastroin-
testinal symptoms. None of the assessed studies
included these complications in their modeling
approach. As clinical data concerning frequency,
severity, and costs of these outcomes are sparse,
their implementation in the model may cause con-
siderable problems and needs further research.
However, any modeling should attempt to make
plausible and explicit assumptions regarding these
outcomes in order for the results to be a valid rep-
resentation of the entire disease process and not
only of parts of it.
Neuroprotective and Mortality Effects
Finally, all models relied on the assumption that the
evaluated treatments do not affect mortality or have
a neuroprotective effect. Further basic and clinical
research is necessary to address these issues in order
to investigate not only the question of how to treat
PD patients but also when to start treatment for
optimizing PD care.
Mortality
All Markov models covered in this review included
an explicit Markov state for death, making it pos-
sible to model mortality. The modeling of back-
ground mortality causes other than PD is essential
to yield valid cost-effectiveness estimates. However,
none of the studies explicitly addressed PD-speciﬁc
mortality. Although it may be reasonable to assume
no treatment effect on mortality, the consideration
of disease-speciﬁc mortality may still alter cost-
effectiveness estimates in models with a long time
horizon through reduced duration of life. It has
been argued that life expectancy may be reduced in
patients with PD compared to the general popula-
tion [60,63,64]. Therefore, future investigators may
want to consider this option in sensitivity analyses.
Health-Related Quality of  Life
All but two [48,50] models included QoL and used
QALYs as the clinical outcome. This raises the
question whether the use of QALYs is an indispen-
sable model feature. Davey et al. showed in their
analysis that pergolide results in a longer stay in
HY stages I–III than bromocriptine and yields cost-
savings of more than Au$1000 per patient [50]. In
this case, it may be justiﬁed that further QALY cal-
culations were suspended because one intervention
dominated the other. However, this dominance
would only hold for the outcome QALY if it could
be assumed that QoL is mainly determined by the
HY stage and that drugs have little differential
inﬂuence on QoL within the HY stages. In any case,
assumptions such as those should be stated explic-
itly and be based on evidence or tested in a sensi-
tivity analysis on drug-related QoL effects. The
other study that did not apply QALYs was the cost-
minimization analysis of Iskedjian and Einarson
[48]. This type of analysis does not contrast incre-
mental costs to incremental clinical outcomes and
therefore implicitly assumes identical clinical out-
comes for both compared strategies. Given the fact
that adverse drug effects differed between the strat-
egies and also may affect the QoL of patients under
treatment, the inclusion of QALYs in the model
would have enhanced the clinical relevance of this
study.
Cost Analysis
Most of the 8 studies focused on direct costs. Only
two evaluated costs due to lost productivity (indi-
rect costs) and implemented them in their models
[48,49]. Two others [52,53] explicitly followed rec-
ommendations for cost-utility analyses [23], which
suggest for the reference case analysis not to con-
sider costs due to productivity losses in the numera-
tor of the cost-utility ratio but rather to use a QoL
measure that already implicitly or explicitly incor-
porates the effects of morbidity on productivity
time in non-monetary terms. This would avoid dou-
ble counting of costs due to lost productivity. Nui-
jten et al. stated that they did not consider indirect
costs because the average age of PD patients was
close to retirement age [51]. Following this exam-
ple, whatever approach is chosen regarding produc-
tivity losses should be explicitly reported. In any
case, the description of expected costs due to pro-
ductivity losses is of additional value for judgments
on societal costs on a macroeconomic level.
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Heterogeneity Bias
All models implicitly assumed homogeneity of pro-
gression and homogeneity of treatment effects in the
patient population. It has been argued that patients
who progress more slowly in the early disease stages
also progress more slowly in the more advanced dis-
ease stages and vice versa [65,66]. If this were true,
all models would be biased through the “heteroge-
neity of progression” bias. It has been shown that
this phenomenon may lead to substantial bias in
favor of the more effective therapy [67]. If this were
also the more expensive therapy, as in most of the
studies included in this review, the cost-effectiveness
ratio calculated with the biased model would be
underestimated. Similarly, if “heterogeneity of treat-
ment effects” is not random but determined by spe-
ciﬁc inherent and ﬁxed patient characteristics (e.g.,
genetic factor or subtype of disease), ignoring this
heterogeneity may lead to bias. However, in this
case, the bias would tend to work against the new
treatment [68]. If the treatment effect is associated
with genetic factors of the patient, this phenomenon
is also called “pharmacogenomics bias.” Sensitivity
analyses in subgroups with higher and lower pro-
gression rates and treatment effects across a plausi-
ble range should be performed to evaluate the
related uncertainty.
Uncertainty
Most decisions in health care are based on imperfect
information and sensitivity analysis must be per-
formed to assess the robustness of the results or
indicate areas where further research may be valu-
able [15]. According to the recommendations of the
Panel on Cost-Effectiveness in Health and Medicine
[23] and the recently published “Principles of Good
Practice for Decision Analytic Modeling in Health
Care Evaluation” [19], every pharmacoeconomic
modeling study should include extensive sensitivity
analyses of key parameters.
In only two models was the variability of input
data analyzed by Monte Carlo simulation (see
Table 2), thus making possible extensive multiple
sensitivity analyses and determination of probabil-
istic uncertainty [46,51]. Although there is no doubt
about the value of such an analysis covering the
overall uncertainty of all relevant models [69], this
type of sensitivity analysis should not replace exten-
sive and thorough deterministic one-way and two-
way sensitivity analyses over plausible ranges of
uncertain parameters [23]. If only the results of the
Monte Carlo simulation are reported in the publi-
cation, the physician or decision-maker may not be
able to interpret the results in the context of his or
her own opinion or for a speciﬁc patient, if one of
these differs from the base-case setting of the pre-
sented analysis.
Funding
Two studies [46,52] did not make any positive or
negative statement about funding or conﬂicts of
interests. The remaining six studies were at least
partially  funded  by  the  industry  manufacturing
the pharmaceuticals for the examined intervention.
Transparency regarding conﬂicts of interests could
be improved by explicitly stating the grant sponsor
and its input into study design, data analysis, man-
uscript preparation, and publication decisions.
Model Validation
Models are only as good as the quality of the input
data. Therefore, after thorough technical testing
(“debugging”), models should be subjected to
internal  validation,  between-model  validation,
and external validation [19,70]. Internal validation
assesses the concordance of the model results and
outcome data from other sources. External valida-
tion includes the comparison with independent out-
come data, which are ideally collected prospectively.
Especially, transition probabilities between disease
states must often be extrapolated beyond the time
horizon of a clinical trial, and therefore, the long-
term model results for disease progression should be
externally validated using epidemiological data
from long-term observational studies or registries.
Even if such data are not yet available for the new
treatment examined in a clinical trial, the investiga-
tors should examine the model validity for the
standard treatment branch.
None of the studies included in this review
reported results from internal or external model val-
idation. We hope that the recommendations on val-
idation recently published by the ISPOR Task Force
on Good Research Practices [19] will motivate deci-
sion-modelers to perform and report validation.
Once different modeling groups evaluate the same
pharmaceutical or surgical treatment strategies, the
comparison of these results will also help to judge
the overall credibility. To date, most of the treat-
ment scenarios have not been evaluated using
different models. This limits the feasibility of
between-model validation. However, as new
insights from future clinical trials and observational
long-term studies change some of the assumptions
or data on which a model is built, it should not
come as a surprise when models do not exactly pre-
dict the results from clinical studies. The ability of
models to adapt to new evidence should not be
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considered as a weakness but as strength of deci-
sion-analytic models.
Complexity versus Simplicity
In this review we have discussed many strengths and
limitations of PD models in general and in speciﬁc.
Some models have useful features that others are
lacking. However, it has to be emphasized, that it is
not the ultimate goal of modeling to reﬂect the most
granular aspect of nature nor are complex models
always better models. It has been repeatedly recom-
mended that a decision model should avoid unnec-
essary complexity to be transparent and to aid
understanding by decision-makers [71–73]. The
ISPOR Task Force on Good Research Practices–
Modeling Studies suggested that “the structure of a
model should be as simple as possible, while cap-
turing underlying essentials of the disease process
and interventions” [19]. However, important states
or events (e.g., adverse events in clinical trials)
should not be omitted because of lack of data or sta-
tistical power, unless the links to these events or
states are contradicted by available evidence [19].
We think that decision-analytic modeling is a
useful tool in clinical decision-making and the eco-
nomic evaluation of interventions in PD. It cannot
replace clinical studies but rather complements
them to better inform physicians and policymakers
about the potential long-term effectiveness and
costs of new and promising interventions.
Conclusions
Based on our systematic review of decision-analytic
models for the evaluation of treatment strategies for
Parkinson’s disease, we conclude that models have
been successfully applied to evaluate pharmaceutical
as well as surgical treatments in PD. In most cases,
Markov models have been used to reﬂect this chronic
and progressive disease. However, most of the mod-
els were lacking at least one important feature of an
adequate decision-analytic framework in PD.
We recommend that models in PD consider a life-
long time horizon, a sufﬁcient spectrum of clinical
outcomes, relevant events and complications, and
disease-speciﬁc mortality. Emphasis should be given
to transparent extrapolation beyond trial data.
Economic evaluations should be complete, include
the societal perspective, and report—among other
results—cost-utility ratios. One-way as well as
multi-way deterministic or probabilistic sensitivity
analyses should be conducted including those on the
effect of heterogeneity of progression and hetero-
geneity of treatment. Internal model validation is
mandatory and external validation should be
attempted. Cross-validation should become stand-
ard, because several PD models have been
published.
Approaches to model treatment effects varied
and were either mediated via reduction of sympto-
matic progression and/or initial symptomatic
improvement or via reduction of adverse effects.
Considering the biology of PD and recommenda-
tions regarding good modeling practice, we believe
that structural bias could be avoided and the sub-
stantial uncertainty in extrapolations could be
reduced in future models, if they contain two sepa-
rate components: 1) the underlying biological proc-
ess, which can presently not be inﬂuenced by
treatment, and 2) HY staging or clinical scales
reﬂecting symptomatic treatment effects. To con-
sider trade-offs in treatment effects on different out-
comes, health states should be chosen in a way that
they could be linked to outcomes such as Hoehn
and Yahr stages, all complications and events of
interest, UPDRS scores, utilities, and costs.
This study was supported by the German Federal Minis-
try of Education and Research, Competence Network
Parkinson-Syndromes [BMBF No. 01GI9901/1]. The
work of Dr Walbert was supported by the Fulbright
Program.
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